At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Matthew Davids, MD, MMSc, discusses considerations for BTK inhibitor resistance and mutations in the treatment of patients with CLL.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Matthew Davids, MD, MMSc, discusses considerations for BTK inhibitor resistance and mutations in the treatment of patients with CLL.
At the 2025 Lymphoma, Leukemia &...